Re: USA: 2013-14 FluView: Influenza Season Weekly Summary, Wks 42-10: 3 New Pediatric Deaths, 68 Total
Re: USA: 2013-14 FluView: Influenza Season Weekly Summary, Wks 42-10: 3 New Pediatric Deaths, 68 Total
Wk 10, ending Mar 8
Influenza-Associated Pediatric Mortality
Three influenza-associated pediatric deaths were reported to CDC during week 10. Two deaths were associated with a 2009 H1N1 virus and occurred during weeks 52 and 7 (weeks ending December 28, 2013 and February 15, 2014). One death was associated with an influenza A virus for which no subtyping was performed and occurred during week 6 (week ending February 1, 2014). From MMWR: ME (1), IL (1), MD (1)
A total of 68 influenza-associated pediatric deaths have been reported during the 2013-2014 season from Chicago [1], New York City [1] and 28 states (AR [4], AZ [1], CA [6]; FL [3], GA [1]; IA [1]; IL [1]; KS [2], KY [1]; LA [5]; MA [2]; MD [1]; ME [1]; MI [2], MS [1], NC [5]; NE [1], NV [1], OK [2]; OR [1], PA [1], SC [2], TN [4]; TX [11]; UT [2]; VA [1]; WI [1]; and WV [2]).
Influenza-associated Hospitalizations:
Between October 1, 2013 and March 8, 2014, 7,910 laboratory-confirmed influenza-associated hospitalizations were reported. This is a rate of 29.2 per 100,000 population. The highest rate of hospitalization remains among adults aged ≥65 years, followed by the 50-64 years and 0-4 years age groups. People 18-64 years accounted for more than 60% of reported hospitalized cases. Among all hospitalizations, 7,434 (94.0%) were associated with influenza A, 397 (5.0%) with influenza B, 29 (0.4%) with influenza A and B co-infection, and 50 (0.6%) had no virus type information. Among those with influenza A subtype information, 77 (2.2%) were H3 and 3,415 (97.8%) were 2009 H1N1.
Clinical findings are preliminary and based on approximately 44% of cases with complete medical chart abstraction. The most commonly reported underlying medical conditions among adults were obesity, metabolic disorders, cardiovascular disease, and chronic lung disease (excluding asthma). Approximately 12% of hospitalized adults had no identified underlying medical conditions. The most commonly reported underlying medical conditions in children were asthma, neurologic disorders, obesity, cardiovascular disease, and chronic lung disease (excluding asthma). Approximately 44% of hospitalized children had no identified underlying medical conditions. Among 486 hospitalized women of childbearing age (15-44 years), 104 (21.4%) were pregnant.
U.S. Virologic Surveillance
No. of specimens tested: 6,372
No. of positive specimens (%): 535 (8.4%)
Positive specimens by type/subtype
Influenza A: 362 (67.7%)
2009 H1N1: 153 (42.3%)
H3: 31 (8.6%)
Subtyping not performed: 178 (49.2%)
Influenza B: 173 (32.3%)
Neuraminidase Inhibitor Resistance Testing Results Since Oct 1, 2013
2009 H1N1: 4155 tested, 40 (1.0%) are resistant
All other samples tested found 0 resistant
Antigenic Characterization*
CDC has antigenically characterized 1,668 influenza viruses [1,415 2009 H1N1 viruses, 170 influenza A (H3N2) viruses, and 83 influenza B viruses] collected by U.S. laboratories since October 1, 2013 by hemagglutination inhibition (HI).
2009 H1N1 [1,415]:
1,414 (99.9%) of 1,415 2009 H1N1 viruses tested were characterized as A/California/7/2009-like, the influenza A (H1N1) component of the 2013-2014 Northern Hemisphere influenza vaccine. One (0.1%) virus showed reduced titers with antiserum produced against A/California/7/2009.
Influenza A (H3N2) [170]:
All 170 influenza A (H3N2) viruses tested have been characterized as A/Texas/50/2012-like, the influenza A (H3N2) component of the 2013-2014 Northern Hemisphere influenza vaccine.
Influenza B [83]: 53 (64%) of the 83 influenza B viruses tested belong to B/Yamagata/16/88-lineage and the remaining 30 (36%) influenza B viruses tested belong to B/Victoria/02/87 lineage.
Yamagata Lineage [53]: 53 influenza B/Yamagata-lineage viruses were characterized as B/ Massachusetts/2/2012-like, which is included as an influenza B component of the 2013-2014 Northern Hemisphere trivalent and quadrivalent influenza vaccines.
Victoria Lineage [30]: 30 influenza B/Victoria-lineage viruses were characterized as B/Brisbane/60/2008-like, which is included as an influenza B component of the 2013-2014 Northern Hemisphere quadrivalent influenza vaccine.
Composition of the 2014-2015 Influenza Vaccine
The World Health Organization (WHO) has recommended vaccine viruses for the 2014-2015 Northern Hemisphere vaccines, and the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) has made recommendations for the composition of the 2014-2015 influenza vaccines to be used in the United States. Both agencies recommend that trivalent vaccines contain an A/California/7/2009-like (2009 H1N1) virus, an A/Texas/50/2012-like (H3N2) virus, and a B/Massachusetts/2/2012-like (B/Yamagata lineage) virus. It is recommended that quadrivalent vaccines containing an additional influenza B virus contain a B/Brisbane/60/2008-like (B/Victoria lineage) virus in addition to the viruses recommended for the trivalent vaccines. These recommendations were based on global influenza virus surveillance data related to epidemiology and antigenic characteristics, serological responses to 2013-2014 seasonal vaccines, and the availability of candidate strains and reagents.
http://www.cdc.gov/flu/weekly/
Re: USA: 2013-14 FluView: Influenza Season Weekly Summary, Wks 42-10: 3 New Pediatric Deaths, 68 Total
Wk 10, ending Mar 8
Influenza-Associated Pediatric Mortality
Three influenza-associated pediatric deaths were reported to CDC during week 10. Two deaths were associated with a 2009 H1N1 virus and occurred during weeks 52 and 7 (weeks ending December 28, 2013 and February 15, 2014). One death was associated with an influenza A virus for which no subtyping was performed and occurred during week 6 (week ending February 1, 2014). From MMWR: ME (1), IL (1), MD (1)
A total of 68 influenza-associated pediatric deaths have been reported during the 2013-2014 season from Chicago [1], New York City [1] and 28 states (AR [4], AZ [1], CA [6]; FL [3], GA [1]; IA [1]; IL [1]; KS [2], KY [1]; LA [5]; MA [2]; MD [1]; ME [1]; MI [2], MS [1], NC [5]; NE [1], NV [1], OK [2]; OR [1], PA [1], SC [2], TN [4]; TX [11]; UT [2]; VA [1]; WI [1]; and WV [2]).
Influenza-associated Hospitalizations:
Between October 1, 2013 and March 8, 2014, 7,910 laboratory-confirmed influenza-associated hospitalizations were reported. This is a rate of 29.2 per 100,000 population. The highest rate of hospitalization remains among adults aged ≥65 years, followed by the 50-64 years and 0-4 years age groups. People 18-64 years accounted for more than 60% of reported hospitalized cases. Among all hospitalizations, 7,434 (94.0%) were associated with influenza A, 397 (5.0%) with influenza B, 29 (0.4%) with influenza A and B co-infection, and 50 (0.6%) had no virus type information. Among those with influenza A subtype information, 77 (2.2%) were H3 and 3,415 (97.8%) were 2009 H1N1.
Clinical findings are preliminary and based on approximately 44% of cases with complete medical chart abstraction. The most commonly reported underlying medical conditions among adults were obesity, metabolic disorders, cardiovascular disease, and chronic lung disease (excluding asthma). Approximately 12% of hospitalized adults had no identified underlying medical conditions. The most commonly reported underlying medical conditions in children were asthma, neurologic disorders, obesity, cardiovascular disease, and chronic lung disease (excluding asthma). Approximately 44% of hospitalized children had no identified underlying medical conditions. Among 486 hospitalized women of childbearing age (15-44 years), 104 (21.4%) were pregnant.
U.S. Virologic Surveillance
No. of specimens tested: 6,372
No. of positive specimens (%): 535 (8.4%)
Positive specimens by type/subtype
Influenza A: 362 (67.7%)
2009 H1N1: 153 (42.3%)
H3: 31 (8.6%)
Subtyping not performed: 178 (49.2%)
Influenza B: 173 (32.3%)
Neuraminidase Inhibitor Resistance Testing Results Since Oct 1, 2013
2009 H1N1: 4155 tested, 40 (1.0%) are resistant
All other samples tested found 0 resistant
Antigenic Characterization*
CDC has antigenically characterized 1,668 influenza viruses [1,415 2009 H1N1 viruses, 170 influenza A (H3N2) viruses, and 83 influenza B viruses] collected by U.S. laboratories since October 1, 2013 by hemagglutination inhibition (HI).
2009 H1N1 [1,415]:
1,414 (99.9%) of 1,415 2009 H1N1 viruses tested were characterized as A/California/7/2009-like, the influenza A (H1N1) component of the 2013-2014 Northern Hemisphere influenza vaccine. One (0.1%) virus showed reduced titers with antiserum produced against A/California/7/2009.
Influenza A (H3N2) [170]:
All 170 influenza A (H3N2) viruses tested have been characterized as A/Texas/50/2012-like, the influenza A (H3N2) component of the 2013-2014 Northern Hemisphere influenza vaccine.
Influenza B [83]: 53 (64%) of the 83 influenza B viruses tested belong to B/Yamagata/16/88-lineage and the remaining 30 (36%) influenza B viruses tested belong to B/Victoria/02/87 lineage.
Yamagata Lineage [53]: 53 influenza B/Yamagata-lineage viruses were characterized as B/ Massachusetts/2/2012-like, which is included as an influenza B component of the 2013-2014 Northern Hemisphere trivalent and quadrivalent influenza vaccines.
Victoria Lineage [30]: 30 influenza B/Victoria-lineage viruses were characterized as B/Brisbane/60/2008-like, which is included as an influenza B component of the 2013-2014 Northern Hemisphere quadrivalent influenza vaccine.
Composition of the 2014-2015 Influenza Vaccine
The World Health Organization (WHO) has recommended vaccine viruses for the 2014-2015 Northern Hemisphere vaccines, and the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) has made recommendations for the composition of the 2014-2015 influenza vaccines to be used in the United States. Both agencies recommend that trivalent vaccines contain an A/California/7/2009-like (2009 H1N1) virus, an A/Texas/50/2012-like (H3N2) virus, and a B/Massachusetts/2/2012-like (B/Yamagata lineage) virus. It is recommended that quadrivalent vaccines containing an additional influenza B virus contain a B/Brisbane/60/2008-like (B/Victoria lineage) virus in addition to the viruses recommended for the trivalent vaccines. These recommendations were based on global influenza virus surveillance data related to epidemiology and antigenic characteristics, serological responses to 2013-2014 seasonal vaccines, and the availability of candidate strains and reagents.
http://www.cdc.gov/flu/weekly/